Multivariate analysis for PFS and for OS (final models)
| . | HR . | 95% CI for HR . | . | |
|---|---|---|---|---|
| Lower . | Upper . | P . | ||
| PFS | ||||
| Duration of last lenalidomide regimen <12 mo | 1.485 | 1.009 | 2.186 | .045 |
| Time since last lenalidomide dose <18 mo | 1.970 | 1.271 | 3.054 | .002 |
| OS | ||||
| Duration of last lenalidomide regimen <12 mo | 1.661 | 1.102 | 2.503 | .015 |
| Time since last lenalidomide dose <18 mo | 1.775 | 1.107 | 2.845 | .017 |
| . | HR . | 95% CI for HR . | . | |
|---|---|---|---|---|
| Lower . | Upper . | P . | ||
| PFS | ||||
| Duration of last lenalidomide regimen <12 mo | 1.485 | 1.009 | 2.186 | .045 |
| Time since last lenalidomide dose <18 mo | 1.970 | 1.271 | 3.054 | .002 |
| OS | ||||
| Duration of last lenalidomide regimen <12 mo | 1.661 | 1.102 | 2.503 | .015 |
| Time since last lenalidomide dose <18 mo | 1.775 | 1.107 | 2.845 | .017 |
HR, hazard ratio.